<code id='16CB2F36E5'></code><style id='16CB2F36E5'></style>
    • <acronym id='16CB2F36E5'></acronym>
      <center id='16CB2F36E5'><center id='16CB2F36E5'><tfoot id='16CB2F36E5'></tfoot></center><abbr id='16CB2F36E5'><dir id='16CB2F36E5'><tfoot id='16CB2F36E5'></tfoot><noframes id='16CB2F36E5'>

    • <optgroup id='16CB2F36E5'><strike id='16CB2F36E5'><sup id='16CB2F36E5'></sup></strike><code id='16CB2F36E5'></code></optgroup>
        1. <b id='16CB2F36E5'><label id='16CB2F36E5'><select id='16CB2F36E5'><dt id='16CB2F36E5'><span id='16CB2F36E5'></span></dt></select></label></b><u id='16CB2F36E5'></u>
          <i id='16CB2F36E5'><strike id='16CB2F36E5'><tt id='16CB2F36E5'><pre id='16CB2F36E5'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:17961
          Stain of a biopsy specimen of a rhabdoid tumor -- health coverage from STAT
          Stain of a biopsy specimen of a rhabdoid tumor. Wikimedia Commons

          Most targeted cancer drugs work like tranquilizer darts, snaring an overzealous gene that has spurred the cell into murderously rapid growth.

          But many tumors don’t have a hyperactive gene. Like the mayhem in “Cat in the Hat,” they are enabled by parental absence. They grow because the genes that are meant to provide discipline, guiding the activity of other genes or self-destructing a cell whose DNA is too damaged, are broken or missing.

          advertisement

          These tumors have bedeviled researchers for decades. Restoring or fixing a protein is far harder than breaking it. And that’s bad news for humanity: Cancer is far more likely to be caused by such “tumor-suppressor” genes than by one gene run amok. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain

          VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Eli Lilly’s Mounjaro succeeds in second weight

          KristofferTripplaar/APThedruggiantEliLillysaidThursdaythatitsdiabetesdrugMounjarohelpedpatientswitht